NanoViricides Reports Progress on Broad-Spectrum Antiviral Candidate NV-387 in Quarterly Filing

NanoViricides, Inc. has filed its Form 10-Q for the quarter ended September 30, 2025, detailing significant progress on its lead drug candidate NV-387, a first-in-class broad-spectrum antiviral designed to resist viral escape by mimicking conserved sulfated proteoglycan receptors used by more than 90% of viruses. This mechanism represents a potential breakthrough in antiviral therapy, addressing major unmet needs across multiple viral diseases including Influenza strains prone to rapid resistance, RSV, Measles, MPox, and gaps in existing Smallpox countermeasures.

The company highlighted current public health concerns that underscore the importance of NV-387's development, specifically noting the dominant A/H3N2 clade K variant and a mismatched seasonal vaccine with historically low efficacy. These challenges demonstrate the critical need for antiviral solutions that maintain effectiveness as viruses evolve, a key limitation of many current antiviral treatments. The broad-spectrum nature of NV-387 could provide protection against multiple viral threats simultaneously, potentially revolutionizing how healthcare systems prepare for and respond to viral outbreaks.

NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company's business model involves licensing technology from TheraCour for specific application verticals of specific viruses, as established at its foundation in 2005. Additional information about the company is available at https://www.nanoviricides.com.

The company's platform technology and programs are based on the TheraCour nanomedicine technology, which NanoViricides holds worldwide exclusive perpetual licenses for several drugs targeting specific human viral diseases including Human Immunodeficiency Virus, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, and certain Coronaviruses. The company intends to obtain licenses for additional viruses including RSV, Poxviruses, and Enteroviruses if initial research proves successful.

NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. However, the company notes that it cannot project an exact date for filing an Investigational New Drug application for any of its drugs due to dependence on external collaborators and consultants.

The development of NV-387 comes at a critical time when viral evolution continues to outpace current treatment options. The ability to target conserved viral receptors rather than specific viral proteins could provide a more durable solution to viral threats, potentially reducing the need for frequent vaccine updates and addressing viruses that currently lack effective treatments. This approach represents a significant shift in antiviral strategy that could have far-reaching implications for global public health preparedness.

Investors can access the latest news and updates relating to NNVC in the company's newsroom at https://ibn.fm/NNVC. The path to typical drug development remains extremely lengthy and requires substantial capital, and as with any pharmaceutical development efforts, there can be no assurance that any of the company's candidates will show sufficient effectiveness and safety for human clinical development or that successful laboratory results will lead to successful clinical trials or products.